home / stock / prld / prld articles

PRLD Articles, Prelude Therapeutics Incorporated

Stock Information
Company Name: Prelude Therapeutics Incorporated
Stock Symbol: PRLD
Market: NASDAQ
Website: preludetx.com
Menu
PRLD PRLD Quote PRLD Short PRLD News PRLD Articles PRLD Message Board
Get PRLD Alerts

News, Short Squeeze, Breakout and More Instantly...
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | Benzinga

WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company...
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference | Benzinga

WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncolog...

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting | Benzinga

Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at ...

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting | Benzinga

WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology compan...
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference | Benzinga

WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncolo...

Prelude Therapeutics Announces $25 Million Private Placement | Benzinga

WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-st...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Prelude Therapeutics Incorporated (NASDAQ: PRLD) and Encourages Investors to Contact the Firm | Benzinga

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Prelude Therapeutics Incorporated (NASDAQ:PRL...
Investor Alert: Abbott Cooper PLLC Investigates Prelude Therapeutics Incorporated; Urges Prelude Stockholders to Contact Abbott Cooper Regarding Their Legal Rights | Benzinga

STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude...

Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference | Benzinga

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage pre...
Next 10